Clinical Trial: Psilocybin Microdosing on Cognition, Mood and Quality of Life

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449351) titled 'Psilocybin Microdosing on Cognition, Mood and Quality of Life' on Feb. 26.

Brief Summary: This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Psychedelic Microdosing Effects on Mood, Cognition...